W

Win Retina | Brian LeBerthon, MD

Research site

(Unclaimed)

Location

234 S. First Avenue, Suite 101, Arcadia, California, United States of America

Site insights

Top conditions

Top treatments

Abicipar Pegol

RO7200220

KHK4951

Vamikibart

Ranibizumab

Aflibercept

ONL1204

Triamcinolone Acetonide

RG7774

Faricimab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 13 total trials

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (ELARA)

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Enrolling

Neovascular Age-Related Macular Degeneration

Diabetic Macular Edema

Drug: Aflibercept 8 mg

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema (ELEVATUM)

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Enrolling

Diabetic Macular Edema

Drug: Faricimab

A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerabi...

Active, not recruiting

Diabetic Macular Edema

Drug: Ranibizumab

Other: Sham Procedure